1.66
+0(+0.00%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.63 |
| Day High | 1.68 |
| Day Low | 1.56 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.22 |
| Volume | 1.03M |
| Average Volume | 5.43M |
| Market Cap | 122.15M |
| PE | -2.52 |
| EPS | -0.66 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 0.9 |
| Change | 0 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $129.99 as of November 09, 2025 at a share price of $1.66. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $1,371.9 as of November 09, 2025 at a share price of $1.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
GlobeNewswire Inc.
Nov 06, 2025 12:30 PM GMT
- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PURCHASE, N.Y.,
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study h
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
GlobeNewswire Inc.
Sep 02, 2025 8:00 PM GMT
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced regist